{"id":5212,"date":"2012-07-04T00:00:00","date_gmt":"2012-07-04T04:00:00","guid":{"rendered":"https:\/\/icesontario.wpengine.com\/journal-articles\/adverse-events-with-intravitreal-injection-of-vascular-endothelial-growth-factor-inhibitors-nested-case-control-study\/"},"modified":"2023-06-14T19:44:43","modified_gmt":"2023-06-14T23:44:43","slug":"adverse-events-with-intravitreal-injection-of-vascular-endothelial-growth-factor-inhibitors-nested-case-control-study","status":"publish","type":"journal_article","link":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/adverse-events-with-intravitreal-injection-of-vascular-endothelial-growth-factor-inhibitors-nested-case-control-study\/","title":{"rendered":"Adverse events with intravitreal injection of vascular endothelial growth factor inhibitors: nested case-control study"},"content":{"rendered":"

Objective<\/strong> — To assess the risk of systemic adverse events associated with intravitreal injections of vascular endothelial growth factor inhibiting drugs.<\/p>\n

Design <\/strong>— Population based nested case-control study.<\/p>\n

Setting<\/strong> — Ontario, Canada.<\/p>\n

Participants <\/strong>— 91, 378 older adults with a history of physician diagnosed retinal disease identified between 1 April 2006 and 31 March 2011. Cases were 1,477 patients admitted to hospital for ischaemic stroke, 2,229 admitted for an acute myocardial infarction, 1,059 admitted or assessed in an emergency department for venous thromboembolism, and 2,623 admitted for congestive heart failure. Event-free controls (at a ratio of 5:1) were matched to cases on the basis of year of birth, sex, history of the outcome in the previous 5 years, and diabetes.<\/p>\n

Main Exposure Measure <\/strong>— Exposure to vascular endothelial growth factor inhibiting drugs identified within 180 days before the index date.<\/p>\n

Results <\/strong>— After adjustment for potential confounders, participants who had ischaemic stroke, acute myocardial infarction, congestive heart failure, or venous thromboembolism were not more likely than control participants to have been exposed to either bevacizumab (adjusted odds ratios of 0.95 (95% confidence interval 0.68 to 1.34) for ischaemic stroke, 1.04 (0.77 to 1.39) for acute myocardial infarction, 0.81 (0.49 to 1.34) for venous thromboembolism, and 1.21 (0.91 to 1.62) for congestive heart failure) or ranibizumab (adjusted odds ratios 0.87 (0.68 to 1.10) for ischaemic stroke, 0.90 (0.72 to 1.11) for acute myocardial infarction, 0.88 (0.67 to 1.16) for venous thromboembolism, and 0.87 (0.70 to 1.07) for congestive heart failure). Similarly, a secondary analysis of exclusive users of bevacizumab or ranibizumab showed no differences in risk between the two drugs (adjusted odds ratios for bevacizumab relative to ranibizumab of 1.03 (0.67 to 1.60) for ischaemic stroke, 1.23 (0.85 to 1.77) for acute myocardial infarction, 0.92 (0.51 to 1.69) for venous thromboembolism, and 1.35 (0.93 to 1.95) for congestive heart failure). These findings were consistent for all but one outcome in subgroup analyses.<\/p>\n

Conclusions —<\/strong> Intravitreal injections of bevacizumab and ranibizumab were not associated with significant risks of ischaemic stroke, acute myocardial infarction, congestive heart failure, or venous thromboembolism.<\/p>\n","protected":false},"excerpt":{"rendered":"

Objective — To assess the risk of systemic adverse events associated with intravitreal injections of vascular endothelial growth factor inhibiting drugs. Design — Population based nested case-control study. Setting — Ontario, Canada. Participants — 91, 378 older adults with a history of physician diagnosed retinal disease identified between 1 April 2006 and 31 March 2011. Cases […]<\/p>\n","protected":false},"template":"","migration-helper-automated":[],"migration-manual":[],"topic":[56],"migration-helper-qa-sample-set":[],"class_list":["post-5212","journal_article","type-journal_article","status-publish","hentry","topic-pharmacoepidemiology-and-drug-safety"],"acf":{"citation":"Campbell R J, Gill SS, Bronskill SE, Paterson JM, Whitehead M, Bell CM. BMJ<\/em>. 2012; 345:e4203. Epub 2012 Jul 4.","source_url":"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3389519\/","ices_scientist":[1203,1251,1159,1172,1100,17132],"site":[6736,6733],"research_program":[6746,6740],"news_release":[7495],"journal_article":[],"atlas":[],"research_report":[],"infographic":[],"video":[],"downloads":null,"links":null,"sitecore_item_id":"DFA23249-6B32-4F15-BEFB-7A26749B21FC","sitecore_item_name":"Adverse-events-with-intravitreal-injection-of-vascular-endothelial-growth-factor-inhibitors","sitecore_field_values":"{\n \"Title\": \"Adverse events with intravitreal injection of vascular endothelial growth factor inhibitors: nested case-control study\",\n \"Short title\": \"Adverse events with intravitreal\",\n \"Citation\": \"

Campbell R J, Gill SS, Bronskill SE, Paterson JM, Whitehead M, Bell CM. BMJ<\/em>. 2012; 345:e4203. Epub 2012 Jul 4.<\/p>\",\n \"Abstract\": \"

Objective<\/strong> — To assess the risk of systemic adverse events associated with intravitreal injections of vascular endothelial growth factor inhibiting drugs.<\/p>n

Design <\/strong>— Population based nested case-control study.<\/p>n

Setting<\/strong> — Ontario, Canada.<\/p>n

Participants <\/strong>— 91, 378 older adults with a history of physician diagnosed retinal disease identified between 1 April 2006 and 31 March 2011. Cases were 1,477 patients admitted to hospital for ischaemic stroke, 2,229 admitted for an acute myocardial infarction, 1,059 admitted or assessed in an emergency department for venous thromboembolism, and 2,623 admitted for congestive heart failure. Event-free controls (at a ratio of 5:1) were matched to cases on the basis of year of birth, sex, history of the outcome in the previous 5 years, and diabetes.<\/p>n

Main Exposure Measure <\/strong>— Exposure to vascular endothelial growth factor inhibiting drugs identified within 180 days before the index date.<\/p>n

Results <\/strong>— After adjustment for potential confounders, participants who had ischaemic stroke, acute myocardial infarction, congestive heart failure, or venous thromboembolism were not more likely than control participants to have been exposed to either bevacizumab (adjusted odds ratios of 0.95 (95% confidence interval 0.68 to 1.34) for ischaemic stroke, 1.04 (0.77 to 1.39) for acute myocardial infarction, 0.81 (0.49 to 1.34) for venous thromboembolism, and 1.21 (0.91 to 1.62) for congestive heart failure) or ranibizumab (adjusted odds ratios 0.87 (0.68 to 1.10) for ischaemic stroke, 0.90 (0.72 to 1.11) for acute myocardial infarction, 0.88 (0.67 to 1.16) for venous thromboembolism, and 0.87 (0.70 to 1.07) for congestive heart failure). Similarly, a secondary analysis of exclusive users of bevacizumab or ranibizumab showed no differences in risk between the two drugs (adjusted odds ratios for bevacizumab relative to ranibizumab of 1.03 (0.67 to 1.60) for ischaemic stroke, 1.23 (0.85 to 1.77) for acute myocardial infarction, 0.92 (0.51 to 1.69) for venous thromboembolism, and 1.35 (0.93 to 1.95) for congestive heart failure). These findings were consistent for all but one outcome in subgroup analyses.<\/p>n

Conclusions —<\/strong> Intravitreal injections of bevacizumab and ranibizumab were not associated with significant risks of ischaemic stroke, acute myocardial infarction, congestive heart failure, or venous thromboembolism.<\/p>n

View full text<\/a><\/p>\",\n \"Keywords\": \"{B711DE54-5056-420D-AA0E-1349F1D88049}|{D4620196-76F6-4AE4-9103-FB996B44FAC4}\",\n \"Related Products\": \"

News Release<\/h2>rn

No increased risk of vascular disease with two popular eye drugs<\/a><\/h3>\",\n \"Research Programs\": \"{CFE36C89-C969-4C23-B5E4-1BA9E5BDC273}|{46DF28D2-EDE8-4DF2-8CC0-87CEF464E435}\",\n \"ICES Locations\": \"{5A12C65D-3CDA-413E-BC94-C1D778156CE6}|{4FCAABBA-14A5-42E6-8F33-BC6C2F1D9908}\",\n \"ICES Scientists\": \"{F8C8C01B-CFDC-4601-804E-F7C502970FCC}|{5B2D929C-DA9B-45B8-8DAA-8150B2E76063}|{68FD9EE5-974B-4CED-A597-82186232FF1D}|{9F60496B-63FD-4BE5-A7EF-C4969D7AACB3}|{4A1034A0-5248-46A2-805E-20FBC57B1237}\",\n \"Posted Date\": \"20120704T000000\"\n}","previous_url":"https:\/\/www.ices.on.ca\/Publications\/Journal-Articles\/2012\/January\/Adverse-events-with-intravitreal-injection-of-vascular-endothelial-growth-factor-inhibitors"},"yoast_head":"\nICES | Adverse events with intravitreal injection of vascular endothelial growth factor inhibitors: nested case-control study<\/title>\n<meta name=\"description\" content=\"Objective — To assess the risk of systemic adverse events associated with intravitreal injections of vascular endothelial growth factor inhibiting\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/adverse-events-with-intravitreal-injection-of-vascular-endothelial-growth-factor-inhibitors-nested-case-control-study\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ICES | Adverse events with intravitreal injection of vascular endothelial growth factor inhibitors: nested case-control study\" \/>\n<meta property=\"og:description\" content=\"Objective — To assess the risk of systemic adverse events associated with intravitreal injections of vascular endothelial growth factor inhibiting\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/adverse-events-with-intravitreal-injection-of-vascular-endothelial-growth-factor-inhibitors-nested-case-control-study\/\" \/>\n<meta property=\"og:site_name\" content=\"ICES\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ICESOntario\/\" \/>\n<meta property=\"article:modified_time\" content=\"2023-06-14T23:44:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2024\/11\/ic-es-data-discovery-better-health-logo.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/adverse-events-with-intravitreal-injection-of-vascular-endothelial-growth-factor-inhibitors-nested-case-control-study\\\/\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/adverse-events-with-intravitreal-injection-of-vascular-endothelial-growth-factor-inhibitors-nested-case-control-study\\\/\",\"name\":\"ICES | Adverse events with intravitreal injection of vascular endothelial growth factor inhibitors: nested case-control study\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#website\"},\"datePublished\":\"2012-07-04T04:00:00+00:00\",\"dateModified\":\"2023-06-14T23:44:43+00:00\",\"description\":\"Objective — To assess the risk of systemic adverse events associated with intravitreal injections of vascular endothelial growth factor inhibiting\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/adverse-events-with-intravitreal-injection-of-vascular-endothelial-growth-factor-inhibitors-nested-case-control-study\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/adverse-events-with-intravitreal-injection-of-vascular-endothelial-growth-factor-inhibitors-nested-case-control-study\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/adverse-events-with-intravitreal-injection-of-vascular-endothelial-growth-factor-inhibitors-nested-case-control-study\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Journal Articles\",\"item\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Adverse events with intravitreal injection of vascular endothelial growth factor inhibitors: nested case-control study\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/\",\"name\":\"ICES\",\"description\":\"POPULATION-BASED HEALTH RESEARCH THAT MAKES A DIFFERENCE\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#organization\"},\"alternateName\":\"Institute for Clinical Evaluative Sciences\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#organization\",\"name\":\"ICES\",\"alternateName\":\"Institute for Clinical Evaluative Sciences\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/ices-logo.png\",\"contentUrl\":\"https:\\\/\\\/www.ices.on.ca\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/ices-logo.png\",\"width\":\"676\",\"height\":\"618\",\"caption\":\"ICES\"},\"image\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/ICESOntario\\\/\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/ices-research-institute\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ICES | Adverse events with intravitreal injection of vascular endothelial growth factor inhibitors: nested case-control study","description":"Objective — To assess the risk of systemic adverse events associated with intravitreal injections of vascular endothelial growth factor inhibiting","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/adverse-events-with-intravitreal-injection-of-vascular-endothelial-growth-factor-inhibitors-nested-case-control-study\/","og_locale":"fr_FR","og_type":"article","og_title":"ICES | Adverse events with intravitreal injection of vascular endothelial growth factor inhibitors: nested case-control study","og_description":"Objective — To assess the risk of systemic adverse events associated with intravitreal injections of vascular endothelial growth factor inhibiting","og_url":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/adverse-events-with-intravitreal-injection-of-vascular-endothelial-growth-factor-inhibitors-nested-case-control-study\/","og_site_name":"ICES","article_publisher":"https:\/\/www.facebook.com\/ICESOntario\/","article_modified_time":"2023-06-14T23:44:43+00:00","og_image":[{"width":1200,"height":675,"url":"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2024\/11\/ic-es-data-discovery-better-health-logo.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/adverse-events-with-intravitreal-injection-of-vascular-endothelial-growth-factor-inhibitors-nested-case-control-study\/","url":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/adverse-events-with-intravitreal-injection-of-vascular-endothelial-growth-factor-inhibitors-nested-case-control-study\/","name":"ICES | Adverse events with intravitreal injection of vascular endothelial growth factor inhibitors: nested case-control study","isPartOf":{"@id":"https:\/\/www.ices.on.ca\/fr\/#website"},"datePublished":"2012-07-04T04:00:00+00:00","dateModified":"2023-06-14T23:44:43+00:00","description":"Objective — To assess the risk of systemic adverse events associated with intravitreal injections of vascular endothelial growth factor inhibiting","breadcrumb":{"@id":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/adverse-events-with-intravitreal-injection-of-vascular-endothelial-growth-factor-inhibitors-nested-case-control-study\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/adverse-events-with-intravitreal-injection-of-vascular-endothelial-growth-factor-inhibitors-nested-case-control-study\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/adverse-events-with-intravitreal-injection-of-vascular-endothelial-growth-factor-inhibitors-nested-case-control-study\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.ices.on.ca\/fr\/"},{"@type":"ListItem","position":2,"name":"Journal Articles","item":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/"},{"@type":"ListItem","position":3,"name":"Adverse events with intravitreal injection of vascular endothelial growth factor inhibitors: nested case-control study"}]},{"@type":"WebSite","@id":"https:\/\/www.ices.on.ca\/fr\/#website","url":"https:\/\/www.ices.on.ca\/fr\/","name":"ICES","description":"POPULATION-BASED HEALTH RESEARCH THAT MAKES A DIFFERENCE","publisher":{"@id":"https:\/\/www.ices.on.ca\/fr\/#organization"},"alternateName":"Institute for Clinical Evaluative Sciences","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ices.on.ca\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.ices.on.ca\/fr\/#organization","name":"ICES","alternateName":"Institute for Clinical Evaluative Sciences","url":"https:\/\/www.ices.on.ca\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ices.on.ca\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2023\/04\/ices-logo.png","contentUrl":"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2023\/04\/ices-logo.png","width":"676","height":"618","caption":"ICES"},"image":{"@id":"https:\/\/www.ices.on.ca\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ICESOntario\/","https:\/\/www.linkedin.com\/company\/ices-research-institute\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/journal_article\/5212","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/journal_article"}],"about":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/types\/journal_article"}],"acf:post":[{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/news_release\/7495"},{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/research_program\/6740"},{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/research_program\/6746"},{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/site\/6733"},{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/site\/6736"},{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/ices_scientist\/17132"},{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/ices_scientist\/1100"},{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/ices_scientist\/1159"},{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/ices_scientist\/1251"},{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/ices_scientist\/1203"}],"wp:attachment":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/media?parent=5212"}],"wp:term":[{"taxonomy":"migration-helper-automated","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/migration-helper-automated?post=5212"},{"taxonomy":"migration-manual","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/migration-manual?post=5212"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/topic?post=5212"},{"taxonomy":"migration-helper-qa-sample-set","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/migration-helper-qa-sample-set?post=5212"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}